Global Translational Regenerative Medicine Market Prospects 2017-2027

トランスレーショナル再生医療の世界市場見通し

◆タイトル:Global Translational Regenerative Medicine Market Prospects 2017-2027
◆商品コード:VGAIN705050
◆調査・発行会社:visiongain
◆発行日:2017年4月
◆ページ数:316
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、トランスレーショナル再生医療の世界市場について調査・分析し、トランスレーショナル再生医療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・トランスレーショナル再生医療の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・トランスレーショナル再生医療の世界市場:セグメント別市場分析
・トランスレーショナル再生医療の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Report Details
The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 316-page report you will receive 107 tables and 66 figures – all unavailable elsewhere.

The 316-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Translational Regenerative Medicine market forecasts from 2017-2027

• Translational Regenerative Medicine regional market forecasts from 2017-2027, covering:
- United States
- Europe
- Asia-Pacific
- Rest of the World

• Global Translational Regenerative Medicine submarket forecasts from 2017-2027 covering:
- Stem Cell Therapies
- Tissue Engineered Products
- Gene Therapies

• Forecasts from 2017-2027 of the leading products in the Global Translational Regenerative Medicine market:
- Osteocel Plus
- Trinity ELITE
- TEMCELL /Prochymal
- Apligraf
- Dermagraft
- Epifix
- ReCell
- Neovasculgen
- Glybera (alipogene tiparvovec)
- IMLYGIC (talimogene laherparepvec)

• Assessment of the leading companies in the Global Translational Regenerative Medicine market:
- Alphatec Spine
- Anterogen
- Athersys
- Avita Medical
- AxoGen
- Medipost
- Mesoblast
- NuVasive
- Ocata Therapeutics
- Organogenesis
- Osiris Therapeutics
- Pharmicell
- Regenerys
- TiGenix
- UniQure
- Vericel Corporation

• SWOT and Porter’s Five Force analysis of the translational regenerative medicine market

Visiongain’s study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

【レポートの目次】

1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Translational Regenerative Medicine
2.1 What Is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation and Specialization
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered the Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signaling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2017-2027
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2016 and 2017
3.3 Global Translational Regenerative Medicine: Market Forecast 2017-2027
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares by Sector 2017-2027
3.3.3 Global Translational Regenerative Medicine Market – Current Developments in the field, 2016 & 2017
3.3.4 Global Translational Regenerative Medicine Market – Current Advancement in the field, 2016 & 2017
3.3.5 Global Translational Regenerative Medicine Market – Current Key Approvals in the field, 2017

4. Stem Cell Therapies: Leading Applications, 2017-2027
4.1 The Global Market for Stem Cell Therapies, 2016 and 2017
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2017-2027
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2017-2027
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2017-2027
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2017-2027
4.8 Development Pipeline for Stem Cell Therapies, 2017-2027
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Adipocell (Bioheart)
4.8.1.8 Cx601 (TiGenix)
4.8.1.9 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.10 Stempeucel (Stempeutics Research)
4.8.1.11 C-Cure (Cardio3 BioSciences)
4.8.1.12 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration and License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 ChondroCelect (TiGenix BV)
4.10 Stem Cells Therapy Market: Drivers and Restraints 2017-2027
5. Tissue Engineering Therapies: Leading Applications, 2017-2027
5.1 The Global Market for Tissue Engineered Therapies, 2016
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2017-2027
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2017-2027
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2017-2027
5.3.5 Epifix (MiMedx)
5.3.5.1 Epifix (MiMedx): Sales Forecast 2017-2027
5.3.6 Epicel (Vericel)
5.3.7 Grafix (Osiris Therapeutics)
5.3.8 MySkin and CyroSkin (Regenerys)
5.3.9 ReCell (Avita Medical)
5.3.9.1 ReCell (Avita Medical): Sales Forecast 2017-2027
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2017-2027
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2017-2027

6. Gene Therapies: Leading Applications, 2017-2027
6.1 The Global Market for Gene Therapies, 2016
6.2 Gene Therapies: Global Market Forecast 2017-2027
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2017-2027
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2017-2027
6.3.5 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.3.5.1 Clinical Trials and Development Efforts for IMLYGIC
6.3.5.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2017-2027
6.4 Development Pipeline for Gene Therapies, 2017-2027
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2017-2027

7. Leading National Markets for Translational Regenerative Medicine, 2017-2027
7.1 The Translational Regenerative Medicine Market by Region
7.1.1 The Global Distribution of Translational Regenerative Medicine in 2016 and 2017
7.2 Leading National Markets: Forecast 2017-2027
7.2.1 Changing Market Shares by Region, 2017-2027
7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2017-2027
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2017-2027
7.4.3 The Regulatory Framework for Regenerative Medicine in the US
7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
7.5.2 European Regenerative Medicine Market: Market Forecast 2017-2027
7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
7.5.4 Regulation of Regenerative Medicine in the European Union
7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
7.5.5.1 Regulation of Stem Cell Research in the UK
7.5.6 Russia: Rising Interest in Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2017-2027
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention into TRM Research in China
7.6.4.2 Regulation of Stem Cell Research in China
7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
7.6.5 Japan: Difficulty in Translating Research into Commercialisation
7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine
7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
7.6.5.3 Regulation of Regenerative Medicine in Japan
7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
7.6.6 India: An Emerging Market for Regenerative Medicine
7.6.6.1 Efforts in Stem Cell Research in India
7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2017-2027

8. Leading Companies in the Translational Regenerative Medicine Market, 2017-2027
8.1 Translational Regenerative Medicine: A Hotbed for Innovation
8.2 Alphatec Spine
8.2.1 Alphatec Spine: Financial and Performance Analysis, 2011-2015
8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
8.3 Anterogen
8.3.1 Anterogen: Pipeline Analysis, 2015
8.4 Athersys
8.4.1 Athersys: Financial and Performance Analysis, 2011-2015
8.4.2 Athersys: Pipeline Analysis, 2015
8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases
8.5 Avita Medical
8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.5.3 Avita Medical: Pipeline Analysis, 2015
8.6 AxoGen
8.6.1 AxoGen: Historical Financial and Performance Analysis, 2011-2015
8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.6.3 AxoGen: Pipeline Analysis, 2015
8.7 Medipost
8.7.1 Medipost: Historical Financial and Performance Analysis, 2011-2015
8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
8.7.3 Medipost: Pipeline Analysis, 2015
8.8 Mesoblast
8.8.1 Mesoblast Product Portfolio, 2015
8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
8.8.3 Mesoblast: Pipeline Analysis, 2015
8.8.3.1 NeoFuse
8.8.3.2 Chondrogen
8.8.3.3 Prochymal / TEMCELL
8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
8.9 NuVasive
8.9.1 NuVasive Product Portfolio, 2015
8.9.2 NuVasive: Historical Financial and Performance Analysis, 2011-2015
8.9.3 NuVasive: Pipeline Analysis, 2015
8.10 Ocata Therapeutics (Acquired by Astellas Pharma Inc.)
8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2011-2015
8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.10.2.1 Retinal Pigment Epithelial Cell Therapy
8.10.3 Ocata’s Other Therapeutic Platforms
8.11 Organogenesis
8.11.1 Organogenesis RM Portfolio, 2015
8.11.2 Organogenesis: Pipeline Analysis, 2015
8.12 Osiris Therapeutics
8.12.1 Osiris Therapeutics: RM Portfolio, 2015
8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2011-2015
8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.13 Pharmicell
8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2011-2015
8.13.2 Pharmicell: Pipeline Analysis, 2015
8.14 Regenerys
8.14.1 Regenerys: RM Portfolio, 2015
8.14.2 Regenerys: Pipeline Analysis, 2015
8.15 TiGenix
8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2015
8.15.2 TiGenix: Pipeline Analysis, 2015
8.16 UniQure
8.16.1 UniQure: Recent Major Acquisition and Collaboration
8.16.2 UniQure: Pipeline Analysis, 2015
8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)
8.17.1 Vericel’s Acquisition of Sanofi’s Regenerative Medicine Business
8.17.2 Vericel: Historical Financial and Performance Analysis, 2011-2015
8.17.3 Vericel Regenerative Medicine Portfolio, 2015
8.18.4 Vericel: Pipeline Analysis, 2015
8.17.2.1 The ixCELL-DCM Clinical Trial

9. Qualitative Analysis for the Global Translational Regenerative Medicine Market, 2017-2027
9.1 Market Factors Influencing the Translational Regenerative Medicine Market
9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2017-2027
9.3 Strengths
9.3.1 Improvements in Regulatory Frameworks
9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
9.3.3 Strong Support from Governments in Multiple Regions
9.3.4 Increasing Ease of Product Commercialisation and Market Access
9.4 Weaknesses
9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
9.4.2 Lack of Funding from Venture Capital
9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
9.5 Opportunities
9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
9.6 Threats
9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
9.6.4 Restraints on Reimbursement May Slow Growth
9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2017-2027
9.7.1 Threat of New Entrants
9.7.2 Threat of Substitutes
9.7.3 Power of Suppliers
9.7.4 Power of Buyers
9.7.5 Rivalry among Competitors

10. Conclusions
10.1 Overview of Current Market Conditions and Market Forecast, 2017-2027
10.2 Leading Regenerative Medicine Segments in 2016 and 2017
10.3 Leading Regions in the Translational Regenerative Medicine Market in 2016 And 2017
10.4 Future Outlook for the Various Sectors within TRM, 2017-2027
10.5 R&D Pipeline Products Crucial to Future Market Growth
10.6 What Does the Future Hold for Regenerative Medicine?

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 (Sample) Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2016-2021
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2015
Table 2.2 Potency and Source of Stem Cells, 2016
Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2016
Table 2.4 Major Types of Stem Cells and Their Properties, 2016
Table 2.5 Terminology for Stem Cell Donor-Types, 2016
Table 2.6 Clinical Trial Phases, 2016
Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2016 and 2017
Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2016-2021
Table 3.3 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2022-2027
Table 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2016-2021, 2022-2027 and 2016-2027
Table 3.5 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2016, 2021 and 2027
Table 3.6 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2016, 2021 and 2027
Table 4.1 Selected Stem Cell Products Currently Available On the Market, 2016
Table 4.2 Stages of Osteogenesis, 2016
Table 4.3 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 4.4 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 4.5 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.7 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 4.8 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 4.9 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 4.10 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 4.11 Stem Cell Therapy Pipeline: Therapies in Development, Clinical Trials
Table 4.12 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 5.1 Selected Tissue Engineering Products Currently Available on the Market, 2015
Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 5.3 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 5.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 5.5 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 5.6 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 5.7 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 5.8 Epifix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 5.9 Epifix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 5.10 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 5.11 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 5.12 Tissue Engineering Pipeline: Therapies in Development, Clinical Trials
Table 5.13 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015
Table 6.1 Currently Available Gene Therapy Products, 2015
Table 6.2 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 6.3 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 6.4 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 6.5 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 6.6 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 6.7 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 6.8 Amgen: Gene Therapy Clinical Trials, 2015
Table 6.9 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2016-2021
Table 6.10 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2022-2027
Table 6.11 Gene Therapy Pipeline: Therapies in Development, Clinical Trials
Table 6.12 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 6.13 Advantegene: Gene Therapy Clinical Trials, 2015
Table 6.14 Spark Therapeutics: Gene Therapy Clinical Trials, 2015
Table 6.15 Recent Developments in Gene Therapy for Use in Diabetes
Table 6.16 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2015
Table 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) and Market Share (%) by Region, 2016 and 2017
Table 7.2 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2016-2021
Table 7.3 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2022-2027
Table 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2016-2021, 2022-2027, 2016-2027
Table 7.5 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2016, 2021 and 2027
Table 7.6 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016, 2021 and 2027
Table 7.7 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 7.8 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 7.9 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016, 2021 and 2027
Table 7.10 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 7.11 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 7.12 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016-2027
Table 7.13 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016-2027
Table 7.16 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 7.17 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2022-2027
Table 8.1 Alphatec Spine: Historical Sales ($m) and Operating Profit / Loss ($m), 2011-2015
Table 8.2 Alphatec Spine: Regenerative Medicine Clinical Trials, 2015
Table 8.3 Anterogen: Regenerative Medicine Clinical Trials, 2015
Table 8.4 Athersys: Historical Sales ($m) 2011-2015
Table 8.5 Athersys: Historical Expenditure and Losses ($m) 2011-2015
Table 8.6 Athersys: Regenerative Medicine Clinical Trials, 2015
Table 8.7 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2011-2015
Table 8.8 Avita Medical: Regenerative Medicine Clinical Trials, 2015
Table 8.9 AxoGen: Historical Sales ($m) and Net Loss ($m), 2011-2015
Table 8.10 AxoGen: Regenerative Medicine Clinical Trials, 2015
Table 8.11 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2011-2015
Table 8.12 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2011-2015
Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2015
Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2011-2015
Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2015
Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2011-2015
Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2015
Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2011-2015
Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015
Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2015
Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2011-2015
Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015
Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2011-2015
Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2015
Table 8.25 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2011-2015
Table 8.26 TiGenix: Regenerative Medicine Clinical Trials, 2015
Table 8.27 UniQure: Regenerative Medicine Clinical Trials, 2015
Table 8.28 Vericel: Historical Sales ($m and AGR%), 2011-2015
Table 8.29 Vericel: Sales by Product ($m) and Revenue Share (%), 2013-2014
Table 8.30 Vericel Corporation: Regenerative Medicine Clinical Trials, 2015
Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2017-2027
Table 10.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2016, 2022, 2027
Table 10.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2016
Table 10.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2016, 2022 and 2027
Table 10.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2016, 2022 and 2027
Table 10.5 Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015

List of Figures
Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2016
Figure 2.1 Brief History of Stem Cell Research, 1900-2016
Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
Figure 2.3 Brief History of Tissue Engineering, 1900-2015
Figure 2.4 Brief History of Gene Therapy, 1970-2015
Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2016 and 2017
Figure 3.2 The Gene Therapy Market: Revenue ($m), 2016 and 2017
Figure 3.3 The Global Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2016-2027
Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2016-2021
Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2022-2027
Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2016-2027
Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2016, 2021 and 2027
Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2016
Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2021
Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2027
Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.4 Epifix Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.5 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.6 Tissue Engineered Therapy Products: Drivers and Restraints, 2017-2027
Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.5 Gene Therapy Products: Market Drivers and Restraints, 2017-2027
Figure 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) by Region, 2016 and 2017
Figure 7.2 Asia-Pacific, Europe, US, and ‘Rest of the World’ Translational Regenerative Medicine Market: Market Forecast ($m), 2016-2027
Figure 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2016-2021
Figure 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2022-2027
Figure 7.5 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2016-2027
Figure 7.6 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2016
Figure 7.7 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2021
Figure 7.8 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2027
Figure 7.9 US Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
Figure 7.10 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.11 European Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
Figure 7.12 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.13 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
Figure 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%), ss2016-2027
Figure 7.15 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.1 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2011-2015
Figure 8.2 Athersys: Historical Sales ($m) 2011-2015
Figure 8.3 Athersys: Historical Revenue, Expenditure and Losses ($m) 2011-2015
Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m), 2011-2015
Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2011-2015
Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014
Figure 8.7 Medipost: Revenue Share by Business Area (%), 2013
Figure 8.8 Medipost: Revenue Share by Business Area (%), 2014
Figure 8.9 Medipost: Revenue Share by Business Area (%), 2015
Figure 8.10 Mesoblast: Historical Sales (AUD m), 2011-2015
Figure 8.11 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2011-2015
Figure 8.12 Ocata Therapeutics: Historical Sales ($m) and Gross Income ($thousand), 2011-2015
Figure 8.13 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2011-2015
Figure 8.14 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2011-2015
Figure 8.15 TiGenix: Historical Sales ($m) and Net Income ($m), 2011-2015
Figure 8.16 Vericel: Historical Sales ($m), 2011-2015 (Limited Scale)
Figure 8.17 Vericel: Revenue Contribution by Product (%) 2014
Figure 9.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016
Figure 10.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2016, 2022 and 2027
Figure 10.2 Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2016
Figure 10.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2016-2027

【レポートのキーワード】

トランスレーショナル再生医療

★調査レポート[トランスレーショナル再生医療の世界市場見通し] ( Global Translational Regenerative Medicine Market Prospects 2017-2027 / VGAIN705050) 販売に関する免責事項
[トランスレーショナル再生医療の世界市場見通し] ( Global Translational Regenerative Medicine Market Prospects 2017-2027 / VGAIN705050) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆